The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Observing late CAR T-cell re-expansion that does not result in malignant transformation
Fabian Müller, MD, University Hospital Erlangen, Erlangen, Germany, discusses the phenomenon of late re-expansion and high-level persistence of CAR T-cells that can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma. Dr Müller highlights that a comprehensive immune-monitoring approach at his institution has enabled the identification of stable T-cell clones with unusual phenotypes that persist over time without resulting in malignant transformation. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
